Daiane Beneduzzi1, Ericka B Trarbach2, Le Min3, Alexander A L Jorge4, Heraldo M Garmes5, Alessandra Covallero Renk6, Marta Fichna7, Piotr Fichna8, Karina A Arantes4, Elaine M F Costa1, Anna Zhang3, Oluwaseun Adeola3, Junping Wen3, Rona S Carroll3, Berenice B Mendonça1, Ursula B Kaiser3, Ana Claudia Latronico1, Letícia F G Silveira9. 1. Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 2. Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Unidade de Endocrinologia Genética/LIM 25, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 3. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts. 4. Unidade de Endocrinologia Genética/LIM 25, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 5. Unidade de Endocrinologia Departamento de Clínica Médica, Faculdade de Ciências Médicas da Universidade de Campinas, Campinas, Brazil. 6. Departamento de Endocrinologia, Hospital Santa Marcelina, São Paulo, Brazil. 7. Institute of Human Genetics, Polish Academy of Sciences and Department of Endocrinology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland. 8. Department of Pediatric Diabetes and Obesity, Poznan University of Medical Sciences, Poznan, Poland. 9. Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Electronic address: leticia.silveira@hc.fm.usp.br.
Abstract
OBJECTIVE: To analyze the GNRHR in patients with normosmic isolated hypogonadotropic hypogonadism (IHH) and constitutional delay of growth and puberty (CDGP). DESIGN: Molecular analysis and in vitro experiments correlated with phenotype. SETTING: Academic medical center. PATIENT(S): A total of 110 individuals with normosmic IHH (74 male patients) and 50 with CDGP. INTERVENTION(S): GNRHR coding region was amplified and sequenced. MAIN OUTCOME MEASURE(S): Novel variants were submitted to in vitro analysis. Frequency of mutations and genotype-phenotype correlation were analyzed. Microsatellite markers flanking GNRHR were examined in patients carrying the same mutation to investigate a possible founder effect. RESULT(S): Eleven IHH patients (10%) carried biallelic GNRHR mutations. In vitro analysis of novel variants (p.Y283H and p.V134G) demonstrated complete inactivation. The founder effect study revealed that Brazilian patients carrying the p.R139H mutation shared the same haplotype. Phenotypic spectrum in patients with GNRHR mutations varied from complete GnRH deficiency to partial and reversible IHH, with a relatively good genotype-phenotype correlation. One boy with CDGP was heterozygous for the p.Q106R variant, which was not considered to be pathogenic. CONCLUSION(S): GNRHR mutations are a frequent cause of congenital normosmic IHH and should be the first candidate gene for genetic screening in this condition, especially in autosomal recessive familial cases. The founder effect study suggested that the p.R139H mutation arises from a common ancestor in the Brazilian population. Finally, mutations in GNRHR do not appear to be involved in the pathogenesis of CDGP.
OBJECTIVE: To analyze the GNRHR in patients with normosmic isolated hypogonadotropic hypogonadism (IHH) and constitutional delay of growth and puberty (CDGP). DESIGN: Molecular analysis and in vitro experiments correlated with phenotype. SETTING: Academic medical center. PATIENT(S): A total of 110 individuals with normosmic IHH (74 male patients) and 50 with CDGP. INTERVENTION(S): GNRHR coding region was amplified and sequenced. MAIN OUTCOME MEASURE(S): Novel variants were submitted to in vitro analysis. Frequency of mutations and genotype-phenotype correlation were analyzed. Microsatellite markers flanking GNRHR were examined in patients carrying the same mutation to investigate a possible founder effect. RESULT(S): Eleven IHHpatients (10%) carried biallelic GNRHR mutations. In vitro analysis of novel variants (p.Y283H and p.V134G) demonstrated complete inactivation. The founder effect study revealed that Brazilian patients carrying the p.R139H mutation shared the same haplotype. Phenotypic spectrum in patients with GNRHR mutations varied from complete GnRH deficiency to partial and reversible IHH, with a relatively good genotype-phenotype correlation. One boy with CDGP was heterozygous for the p.Q106R variant, which was not considered to be pathogenic. CONCLUSION(S): GNRHR mutations are a frequent cause of congenital normosmic IHH and should be the first candidate gene for genetic screening in this condition, especially in autosomal recessive familial cases. The founder effect study suggested that the p.R139H mutation arises from a common ancestor in the Brazilian population. Finally, mutations in GNRHR do not appear to be involved in the pathogenesis of CDGP.
Authors: L C Layman; D P Cohen; M Jin; J Xie; Z Li; R H Reindollar; S Bolbolan; D P Bick; R R Sherins; L W Duck; L C Musgrove; J C Sellers; J D Neill Journal: Nat Genet Date: 1998-01 Impact factor: 38.330
Authors: Ericka B Trarbach; Ana Paula Abreu; Leticia Ferreira Gontijo Silveira; Heraldo Mendes Garmes; Maria Tereza M Baptista; Milena Gurgel Teles; Elaine M F Costa; Moosa Mohammadi; Nelly Pitteloud; Berenice B Mendonca; Ana Claudia Latronico Journal: J Clin Endocrinol Metab Date: 2010-05-12 Impact factor: 5.958
Authors: Astrid U Meysing; Haruhiko Kanasaki; Gregoy Y Bedecarrats; James S Acierno; P Michael Conn; Kathryn A Martin; Stephanie B Seminara; Janet E Hall; William F Crowley; Ursula B Kaiser Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Grégoy Y Bédécarrats; Katja D Linher; Jo Ann Janovick; Milena Beranova; Faiza Kada; Stephanie B Seminara; P Michael Conn; Ursula B Kaiser Journal: Mol Cell Endocrinol Date: 2003-07-31 Impact factor: 4.102
Authors: L F G Silveira; P M Stewart; M Thomas; D A Clark; P M G Bouloux; G S MacColl Journal: J Clin Endocrinol Metab Date: 2002-06 Impact factor: 5.958
Authors: Ines L Sedlmeyer; Celeste Leigh Pearce; Julie A Trueman; Johannah L Butler; Todd Bersaglieri; Andrew P Read; Peter E Clayton; Laurence N Kolonel; Brian E Henderson; Joel N Hirschhorn; Mark R Palmert Journal: J Clin Endocrinol Metab Date: 2004-11-16 Impact factor: 5.958
Authors: Jin-Ho Choi; Ravikumar Balasubramanian; Phil H Lee; Natalie D Shaw; Janet E Hall; Lacey Plummer; Cassandra L Buck; Marie-Laure Kottler; Katarzyna Jarzabek; Sławomir Wołczynski; Richard Quinton; Ana Claudia Latronico; Catherine Dode; Tsutomu Ogata; Hyung-Goo Kim; Lawrence C Layman; James F Gusella; William F Crowley Journal: J Clin Endocrinol Metab Date: 2015-07-24 Impact factor: 5.958
Authors: Bin Yang; Leilei Cui; Miguel Perez-Enciso; Aleksei Traspov; Richard P M A Crooijmans; Natalia Zinovieva; Lawrence B Schook; Alan Archibald; Kesinee Gatphayak; Christophe Knorr; Alex Triantafyllidis; Panoraia Alexandri; Gono Semiadi; Olivier Hanotte; Deodália Dias; Peter Dovč; Pekka Uimari; Laura Iacolina; Massimo Scandura; Martien A M Groenen; Lusheng Huang; Hendrik-Jan Megens Journal: Genet Sel Evol Date: 2017-09-21 Impact factor: 4.297
Authors: Cheng Xu; Andrea Messina; Emmanuel Somm; Hichem Miraoui; Tarja Kinnunen; James Acierno; Nicolas J Niederländer; Justine Bouilly; Andrew A Dwyer; Yisrael Sidis; Daniele Cassatella; Gerasimos P Sykiotis; Richard Quinton; Christian De Geyter; Mirjam Dirlewanger; Valérie Schwitzgebel; Trevor R Cole; Andrew A Toogood; Jeremy Mw Kirk; Lacey Plummer; Urs Albrecht; William F Crowley; Moosa Mohammadi; Manuel Tena-Sempere; Vincent Prevot; Nelly Pitteloud Journal: EMBO Mol Med Date: 2017-10 Impact factor: 12.137